Canaccord Genuity has reiterated its 'Buy' rating for ACADIA Pharmaceuticals (ACAD), signaling continued confidence in the company's stock.

Acadia Pharmaceuticals has reaffirmed its 2026 total revenue guidance of $1.22 billion to $1.28 billion as the readout for its remlifanserin Phase II ADP trial approaches.

ACADIA (ACAD) stock has been upgraded to a 'Buy' rating after experiencing a recent pullback in the market.

Wolfe Research has noted conviction-driven opportunities within ACADIA Pharmaceuticals Inc.’s (ACAD) therapeutic domains, suggesting potential for growth.

Insider trading activities have been reported for prominent companies including Palo Alto Networks, Taiwan Semiconductor, Sony, and Acadia Pharmaceuticals.

ACADIA Pharmaceuticals provided highlights from its first-quarter earnings call.

RBC Capital Markets has slightly trimmed its price target for ACADIA Pharmaceuticals, citing seasonal biotech headwinds. The firm also cut its price target for Galapagos NV to $28, while maintaining a Sector Perform rating ahead of its Q1 earnings.

A summary of ACADIA Pharmaceuticals Inc.'s earnings call for the fourth quarter of 2025, outlining financial performance and recent updates.

Acadia Pharmaceuticals stock experienced a significant surge today, attracting investor attention.

The complete transcript of Acadia Pharmaceuticals' first-quarter 2026 earnings call is presented, covering financial outcomes and pipeline updates.

Acadia Pharmaceuticals has received an upgrade, with analysts citing an improved risk-reward profile for the company following a recent pullback in its stock.

Acadia Pharmaceuticals has set a 2026 revenue target of up to $1.28 billion, driven by the advancement of DAYBUE STIX and NUPLAZID growth initiatives.